These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Rapid screening of phenotypic resistance to nevirapine by direct analysis of HIV type 1 reverse transcriptase activity in plasma. Vázquez-Rosales G; García Lerma JG; Yamamoto S; Switzer WM; Havlir D; Folks TM; Richman DD; Heneine W AIDS Res Hum Retroviruses; 1999 Sep; 15(13):1191-200. PubMed ID: 10480632 [TBL] [Abstract][Full Text] [Related]
5. Genotypic and phenotypic nevirapine resistance correlates with virological failure during salvage therapy including abacavir and nevirapine. Jørgensen LB; Katzenstein TL; Gerstoft J; Mathiesen LR; Pedersen C; Nielsen C Antivir Ther; 2000 Sep; 5(3):187-94. PubMed ID: 11075938 [TBL] [Abstract][Full Text] [Related]
6. A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy. Paredes R; Puertas MC; Bannister W; Kisic M; Cozzi-Lepri A; Pou C; Bellido R; Betancor G; Bogner J; Gargalianos P; Bánhegyi D; Clotet B; Lundgren J; Menéndez-Arias L; Martinez-Picado J; J Infect Dis; 2011 Sep; 204(5):741-52. PubMed ID: 21844300 [TBL] [Abstract][Full Text] [Related]
7. In vitro anti-HIV-1 synergy between non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz. Kollmann C; Tremblay C; Giguel F; Chou TC; Hirsch MS Antivir Ther; 2001 Jun; 6(2):143-4. PubMed ID: 11491419 [No Abstract] [Full Text] [Related]
9. Should we include connection domain mutations of HIV-1 reverse transcriptase in HIV resistance testing. Götte M PLoS Med; 2007 Dec; 4(12):e346. PubMed ID: 18052605 [TBL] [Abstract][Full Text] [Related]
10. Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy. Harrigan PR; Hertogs K; Verbiest W; Larder B; Yip B; Brumme ZL; Alexander C; Tilley J; O'Shaughnessy MV; Montaner JS Antivir Ther; 2003 Oct; 8(5):395-402. PubMed ID: 14640386 [TBL] [Abstract][Full Text] [Related]
11. Evolution of HIV-1 multidrug-resistant genotypes during combination therapy and after the cessation of antiretroviral drugs. Yahi N; Tourrès C; Tivoli N; Colson P; Dhiver C; Quinson AM; Tamalet C AIDS; 2000 Dec; 14(18):2943-5. PubMed ID: 11153678 [No Abstract] [Full Text] [Related]
12. Emergence and genetic evolution of HIV-1 variants with mutations conferring resistance to multiple reverse transcriptase and protease inhibitors. Cabana M; Clotet B; Martínez MA J Med Virol; 1999 Dec; 59(4):480-90. PubMed ID: 10534730 [TBL] [Abstract][Full Text] [Related]
13. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Piyavong B; Chumpathat N; Chantratita W Clin Infect Dis; 2007 Feb; 44(3):447-52. PubMed ID: 17205457 [TBL] [Abstract][Full Text] [Related]
14. Current insights into reverse transcriptase inhibitor-associated resistance. Wainberg MA; White AJ Antivir Ther; 2001; 6 Suppl 2():11-9. PubMed ID: 11678474 [No Abstract] [Full Text] [Related]
15. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. Bannister WP; Ruiz L; Cozzi-Lepri A; Mocroft A; Kirk O; Staszewski S; Loveday C; Karlsson A; Monforte Ad; Clotet B; Lundgren JD; AIDS; 2008 Jan; 22(3):367-76. PubMed ID: 18195563 [TBL] [Abstract][Full Text] [Related]
16. Lamivudine resistance of HIV type 1 does not delay development of resistance to nonnucleoside HIV type 1-specific reverse transcriptase inhibitors as compared with wild-type HIV type 1. Jonckheere H; Witvrouw M; De Clercq E; Anné J AIDS Res Hum Retroviruses; 1998 Feb; 14(3):249-53. PubMed ID: 9491915 [TBL] [Abstract][Full Text] [Related]